Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 ...
Pfizer Inc ((PFE)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...
Facing the loss of exclusivity on key products, Pfizer has pulled forward its lead obesity asset into Phase III and targeted ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
Pfizer Inc. (NYSE:PFE) on Friday released results from the Phase 3 THRIVE-131 study evaluating inclacumab, an investigational P-selectin inhibitor, in patients 16 years of age and older with sickle ...
Boston-based Akili Interactive Labs and Pfizer have released data from a collaborative study showing the use of Akili’s digital, cognitive measurement platform can detect biomarkers of Alzheimer’s ...
An analysis of safety data suggests that Abrysvo, the Pfizer respiratory syncytial virus (RSV) RSVpreF vaccine, does not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback